Navigation Links
Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group

VANCOUVER, Jan. 9 /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic tests, announced today that it has signed a collaborative agreement with the United Kingdom Critical Care Genomics (UKCCG) Group. The agreement focuses on the continued development of Sirius' pharmacogenomic diagnostic for responsiveness to recombinant activated Protein C (sold by Eli Lilly and Company under the trademark Xigris(R)).

"The UKCCG group is conducting a large genomic association study looking at severe life-threatening infections and sepsis. This new collaboration with the UKCCG group will allow Sirius Genomics to significantly advance the development of our diagnostic by accessing the comprehensive database that the UKCCG group has compiled. We are delighted to be working with the UKCCG group to further our progress towards the commercialization of our first product," commented Dr. Brad Popovich, President and CEO of Sirius Genomics.

"The collaboration with Sirius Genomics is in direct alignment with our objective to disseminate and promote understanding of functional genomics in the wider intensive care community," stated Professor Charles Hinds, one of the Principal Investigators of the UKCCG Group. "We are very excited to be working with Sirius Genomics on this new collaboration."

Financial terms of the agreement were not disclosed.

About UKCCG:

The UKCCG Group is a collaborative consortium composed of multiple investigators, collaborators and members throughout the United Kingdom representing more than 35 hospitals. The group's primary objective is to undertake clinical functional genomics research in the critically ill and to develop related collaborative, laboratory based research projects with scientific colleagues.

About Sirius Genomics:

Sirius Genomics is a drug-enabling company that excels at developing pharmacogenomic (PGx) tests that lead to better patient outcomes through personalized medicine. Sirius' business focus is on generating value through improving the safety and effectiveness of pharmaceutical compounds. The Company's expert medical and business team correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SOURCE Sirius Genomics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
4. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
5. ( Announces Upcoming Interview With CEO of DNAPrint Genomics
6. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
9. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
10. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... announced that it has received a Phase I Small Business Innovative Research (SBIR) ... Institute of General Medical Sciences (NIGMS), will fund the development of a technique ...
(Date:10/13/2015)... Oct. 13, 2015  According to Kalorama Information, ... reach $102 billion by the end of 2015. ... health industry, as it is estimated that approximately ... laboratory tests. In addition to diagnosing patients, clinical ... disease progression, monitor drug treatment and conditions, and ...
(Date:10/13/2015)... NC (PRWEB) , ... October 13, 2015 , ... ... intensity focused ultrasound (HIFU) technologies, announced today that it received de novo clearance ... in the U.S. for the ablation of prostate tissue. Sonablate® is the ...
(Date:10/12/2015)... , Oct. 12, 2015  Amgen (NASDAQ: AMGN ... from an exploratory sub-study of the previously reported romosozumab Phase ... an oral plenary session at the American Society for Bone ... Seattle . 2 --> ... sub-study data showed that, at month 12, the investigational bone-forming ...
Breaking Biology Technology:
(Date:10/12/2015)... October 12, 2015 NXTD ) ("NXT-ID" ... growing mobile commerce market, reports on the recent SNS Future ... . --> NXTD ) ("NXT-ID" or the "Company"), ... market, reports on the recent SNS Future in Review Conference ... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ...
(Date:10/8/2015)... Oktober 2015 Die Track Group, ... des Bereiches Tracking, hat heute bekannt gegeben, ... Virginias (Department of Corrections – DOC) unterzeichnet ... alle Strafen geliefert werden, die der Behörde ... für den Amerikanischen Kontinent der Track Group. ...
(Date:10/6/2015)... SALT LAKE CITY , Oct. 6, 2015 /PRNewswire/ ... solutions company, announced today that it has signed a ... electronic monitoring services across the full range of sentences ... Track Group,s President of the Americas. "This contract with ... Eastern region of the US and advances our position ...
Breaking Biology News(10 mins):